istock-896469402-stuart-ritchie

Stuart Ritchie / iStockphoto.com

30 August 2018Americas

FDA warns 21 websites over misbranded opioid drugs

The US Food and Drug Administration (FDA) has warned 21 websites over the illegal marketing of misbranded versions of opioid medications.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Emergent BioSolutions to buy Adapt Pharma for $735m

30 August 2018 Life sciences company Emergent BioSolutions announced plans to acquire Adapt Pharma earlier this week, in what the company said was an effort to combat the public health threat from opioid overdose.

FDA and DEA warn over sale of misbranded opioid drugs

1 October 2019 The US Food and Drug Administration and Drug Enforcement Administration have issued joint warning letters to four online networks which allegedly sell unapproved and misbranded versions of medicines.

More on this story

Emergent BioSolutions to buy Adapt Pharma for $735m

30 August 2018 Life sciences company Emergent BioSolutions announced plans to acquire Adapt Pharma earlier this week, in what the company said was an effort to combat the public health threat from opioid overdose.

FDA and DEA warn over sale of misbranded opioid drugs

1 October 2019 The US Food and Drug Administration and Drug Enforcement Administration have issued joint warning letters to four online networks which allegedly sell unapproved and misbranded versions of medicines.

More on this story

Emergent BioSolutions to buy Adapt Pharma for $735m

30 August 2018 Life sciences company Emergent BioSolutions announced plans to acquire Adapt Pharma earlier this week, in what the company said was an effort to combat the public health threat from opioid overdose.

FDA and DEA warn over sale of misbranded opioid drugs

1 October 2019 The US Food and Drug Administration and Drug Enforcement Administration have issued joint warning letters to four online networks which allegedly sell unapproved and misbranded versions of medicines.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York